Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149415 | 0.85 | ERN1 (0.59) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL1637980 | 0.85 | ERN1 (0.59) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL1527154 | 0.82 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL31195180 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL1534505 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL3466295 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL29683824 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3658867 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5645697 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL10658941 | 0.78 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933519-B | Method for improving yield of 3-bromo-2-hydroxy-4-methoxybenzaldehyde by adopting titanium tetrachloride | 大理大学 | 2024-08-06 | — | — | CN | claimed |
| CN-117024389-A | Total synthesis method of coumarin compound trans-dehydroosthol | 大理大学 | 2023-11-10 | — | — | CN | claimed |
| CN-115232094-B | Synthesis method of coumarin compound Murraol | 大理大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115232094-A | Synthetic method of coumarin compound Murroal | 大理大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114933519-A | Method for increasing yield of 3-bromo-2-hydroxy-4-methoxybenzaldehyde by adopting titanium tetrachloride | 大理大学 | 2022-08-23 | — | — | CN | claimed |
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025007873-A1 | KAT6 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-114933519-B | Method for improving yield of 3-bromo-2-hydroxy-4-methoxybenzaldehyde by adopting titanium tetrachloride | 大理大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-114933519-B | Method for improving yield of 3-bromo-2-hydroxy-4-methoxybenzaldehyde by adopting titanium tetrachloride | 大理大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-114933519-B | Method for improving yield of 3-bromo-2-hydroxy-4-methoxybenzaldehyde by adopting titanium tetrachloride | 大理大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-117024389-A | Total synthesis method of coumarin compound trans-dehydroosthol | 大理大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | disclosed |
| EP-1438281-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | Oxigene, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003035008-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | OXIGENE, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5302700-A | Site-specific; couple with macromolecules for diagnostic, therapeutic or investigative purposes | DUKE UNIVERSITY (US) | 1994-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | ERN1 3673/4885TLR2 1863/4885TLR1 204/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | ERN1 1399/4885TLR2 4029/4885TLR1 4588/4885 |
| US-20040181075-A1 | Process of making chalcone derivatives | CYP2B6, LSS, CYP2E1 | ERN1 2696/4885TLR2 3616/4885TLR1 4256/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ERN1 1076/4885TLR2 2718/4885TLR1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.